Olodanrigan (EMA401)
For research use only.
Catalog No.S0326 Synonyms: PD-126055, Olodanrigan free acid, (S) PD-126055
CAS No. 1316755-16-4
Olodanrigan (EMA401, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
Purity & Quality Control
Choose Selective Angiotensin Receptor Inhibitors
Biological Activity
| Description | Olodanrigan (EMA401, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. |
|---|
Protocol
References
Solubility (25°C)
Chemical Information
| Molecular Weight | |
|---|---|
| Formula | |
| CAS No. | 1316755-16-4 |
| Storage |
powder in solvent |
| Synonyms | PD-126055, Olodanrigan free acid, (S) PD-126055 |
| Smiles | COC1=C(C2=C(CN(C(C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5 |
In vivo Formulation Calculator (Clear solution)
| Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment) | ||||||||||
| Dosage | mg/kg |  |
Average weight of animals | g | |
Dosing volume per animal | ul | |
Number of animals | |
| Step 2: Enter the in vivo formulation () | ||||||||||
| % DMSO % % Tween 80 % ddH2O | ||||||||||
| CalculateReset | ||||||||||
Calculation results:
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Clinical Trial Information
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT04675398 | Not yet recruiting | Device: Summit RC+S | Parkinson Disease | University of California San Francisco|Michael J. Fox Foundation for Parkinson''s Research|Burroughs Wellcome | December 1 2021 | Not Applicable |
| NCT04287543 | Withdrawn | Drug: Melatonin|Drug: Placebos | Parkinson Disease | Instituto Mexicano del Seguro Social | May 2021 | Phase 2|Phase 3 |
| NCT04620980 | Not yet recruiting | Diagnostic Test: targeted resequencing | Parkinson Disease | Neuromed IRCCS | March 1 2021 | -- |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
